• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by NuCana plc

    4/18/25 6:04:29 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    NuCana plc

    (Name of Issuer)


    Ordinary Shares, nominal value (pound)0.04 per share

    (Title of Class of Securities)


    67022C205

    (CUSIP Number)


    Jeffrey Ferguson
    The Carlyle Group, 1001 Pennsylvania Avenue, NW,Suite 220 S
    Washington, DC, 20004
    (202) 729-5626

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/18/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    The Carlyle Group Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Carlyle Holdings I GP Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Carlyle Holdings I GP Sub L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Limited Liability Company


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Carlyle Holdings I L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    CG Subsidiary Holdings L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Limited Liability Company


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    TC Group, L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Limited Liability Company


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Carlyle Investment Management L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Limited Liability Company


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Carlyle Genesis UK LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Limited Liability Company


    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Abingworth LLP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    67022C205


    1 Name of reporting person

    Abingworth Bioventures VII LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,430,062.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,430,062.00
    11Aggregate amount beneficially owned by each reporting person

    3,430,062.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.4 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value (pound)0.04 per share
    (b)Name of Issuer:

    NuCana plc
    (c)Address of Issuer's Principal Executive Offices:

    3 Lochside Way, Edinburgh, UNITED KINGDOM , EH12 9DT.
    Item 1 Comment:
    This Amendment No. 2 to Schedule 13D ("Amendment No. 2") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on September 28, 2020 (as amended to date, the "Schedule 13D"), relating to the Ordinary Shares, nominal value (pound)0.04 per share (the "Ordinary Shares"), of NuCana, plc, a public limited company incorporated in England and Wales (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The information contained on the cover pages is incorporated by reference into this Item 5. The percentage of Ordinary Shares beneficially owned and reported herein is based on 142,037,199 Ordinary Shares outstanding as of December 31, 2024, as disclosed in the Issuer's annual report on Form 20-F filed on March 20, 2025. The securities reported herein include (i) 3,333,333 Ordinary Shares represented by American Depository Shares held of record by Abingworth Bioventures VII LP, (ii) 96,189 Ordinary Shares underlying stock options exercisable within 60 days as of the date hereof, and (iii) 540 Ordinary Shares represented by American Depository Shares held of record by Bali Muralidhar for the benefit of Abingworth Bioventures VII LP and which may be deemed to be beneficially owned by Abingworth Bioventures VII LP. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record and beneficially owned by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.
    (b)
    The information contained on the cover pages is incorporated by reference into this Item 5.
    (c)
    During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Ordinary Shares.
    (d)
    None.
    (e)
    As of March 20, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding Ordinary Shares.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 3: Power of Attorney.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Carlyle Group Inc.
     
    Signature:/s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Chief Financial Officer
    Date:04/18/2025
     
    Carlyle Holdings I GP Inc.
     
    Signature:/s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Managing Director and Chief Financial Officer
    Date:04/18/2025
     
    Carlyle Holdings I GP Sub L.L.C.
     
    Signature:By: Carlyle Holdings I GP Inc., its sole member, /s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Managing Director and Chief Financial Officer
    Date:04/18/2025
     
    Carlyle Holdings I L.P.
     
    Signature:/s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Managing Director
    Date:04/18/2025
     
    CG Subsidiary Holdings L.L.C.
     
    Signature:/s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Managing Director
    Date:04/18/2025
     
    TC Group, L.L.C.
     
    Signature:/s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Managing Director
    Date:04/18/2025
     
    Carlyle Investment Management L.L.C.
     
    Signature:/s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Chief Financial Officer
    Date:04/18/2025
     
    Carlyle Genesis UK LLC
     
    Signature:By: Carlyle Investment Management L.L.C., its sole member, /s/ Anne Frederick, attorney-in-fact
    Name/Title:John C. Redett, Chief Financial Officer
    Date:04/18/2025
     
    Abingworth LLP
     
    Signature:/s/ John Heard
    Name/Title:John Heard, Authorized Signatory
    Date:04/18/2025
     
    Abingworth Bioventures VII LP
     
    Signature:/s/ John Heard
    Name/Title:John Heard, Authorized Signatory
    Date:04/18/2025
    Get the next $NCNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    SEC Filings

    See more
    • SEC Form 424B4 filed by NuCana plc

      424B4 - NuCana plc (0001709626) (Filer)

      5/7/25 7:32:35 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NuCana plc

      EFFECT - NuCana plc (0001709626) (Filer)

      5/6/25 12:15:12 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NuCana plc

      EFFECT - NuCana plc (0001709626) (Filer)

      5/6/25 12:15:13 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NuCana plc

      SC 13G/A - NuCana plc (0001709626) (Subject)

      10/4/24 10:14:46 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NuCana plc (Amendment)

      SC 13D/A - NuCana plc (0001709626) (Subject)

      2/27/24 4:29:36 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NuCana plc (Amendment)

      SC 13G/A - NuCana plc (0001709626) (Subject)

      2/14/24 4:26:01 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    See more

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

      EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

      11/1/21 4:01:00 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

      EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

      8/10/21 8:00:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Prices $7 Million Registered Direct Offering

      EDINBURGH, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise price of $0.8068 per share and (ii) a Series B Warrant to purchase one (1) ADS at an initial exercise price of $1.61 per share. The combined public offering price of each ADS together with the accompa

      5/6/25 8:30:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines. "Throughout 2024, we shared mul

      3/20/25 4:01:49 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

      Experienced Healthcare Executive to Lead Finance Organization Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). "We are delighted to welcome Don to our executive team," said Greg Kunst, Aurion's CEO. "Don's track record of strategic and operational financial leadership, coupled with his extensive experience as a healthcare investment banker, make him an ideal addition to Aurion." "I'm thrilled to join Aurion as CFO," said Don Munoz. "I believe that Aurion's l

      2/10/25 7:00:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana downgraded by William Blair

      William Blair downgraded NuCana from Outperform to Mkt Perform

      8/30/24 7:44:58 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana downgraded by Cowen & Co.

      Cowen & Co. downgraded NuCana from Outperform to Market Perform

      3/3/22 6:12:40 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on NuCana with a new price target

      HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      11/24/21 6:13:12 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care